Remepy reported Phase IIa clinical trial results for Hybridopa (levodopa/carbidopa plus DopApp), its drug-software combination for Parkinson's disease, showing a statistically significant reduction in motor and non-motor symptoms versus levodopa alone — data now published in Brain Communications that the company said support advancing to a pivotal Phase III program.
The study, published under the title "Neural correlates of Parkinson's improvements after combined digital-levodopa therapy: a pilot study", was a three-week, randomized, double-blind, placebo-controlled Phase IIa trial enrolling 41 patients aged 45 to 80 with Parkinson's disease. All participants continued an unchanged levodopa dose (150–1,500 mg daily) and were randomized to receive either the DopApp digital protocol or a placebo application alongside their existing therapy.
Participants in the Hybridopa arm achieved a mean reduction of 9.7 points on the MDS-UPDRS Parts I+II+III composite scale, compared with a 1.95-point reduction in the control group (p=0.0005). The MDS-UPDRS is the standard clinical instrument for rating Parkinson's disease severity across motor, daily living, and non-motor domains, and a five-point change is widely considered a clinically meaningful threshold. Ninety percent of Hybridopa participants met that threshold, though the press release did not disclose the corresponding responder rate in the control arm.
Functional MRI neuroimaging conducted as part of the study showed strengthening of functional connectivity in motor and limbic brain circuits among Hybridopa-treated patients, correlating with improvements in both motor control and mood-related outcomes. The company described these findings as early mechanistic evidence that the digital component may reinforce dopaminergic treatment through targeted neuroplasticity, though the study was not powered or designed to establish causality for those imaging observations. Safety data were not reported in the press release.
An additional exploratory finding indicated that greater patient engagement with specific DopApp modules corresponded with domain-specific clinical improvements, a pattern the company cited as evidence for the personalized nature of the intervention. Such engagement-outcome correlations in open digital health studies are difficult to interpret without controlling for adherence-related confounding.
What Hybridopa is and how it works
Hybridopa combines immediate-release levodopa/carbidopa — the pharmacological backbone of Parkinson's motor symptom treatment for more than five decades — with DopApp, a mobile application delivering structured, multimodal daily protocols covering physical, cognitive, behavioral, and rehabilitative exercises. Carbidopa inhibits peripheral aromatic L-amino acid decarboxylase, reducing conversion of levodopa to dopamine outside the brain and increasing CNS delivery, where levodopa is decarboxylated to dopamine to restore striatal dopaminergic tone.
The digital component is not a passive adherence tool. According to Remepy, DopApp uses adaptive protocols that respond to patient performance, behavior, and clinical status, with the aim of delivering consistent multidisciplinary care in home settings at scale. The company frames this integration as a "Hybrid Drug" — a regulatory and commercial category it is actively defining, combining a pharmaceutical with a Software as a Medical Device (SaMD) component under a single prescription.